[Is there a role for prophylactic antibiotic treatment with macrolides in bronchiectasis?]
Mélanie Bochet1, Nicolas Garin, Jean-Paul Janssens
1Service de Médecine Interne Générale, Département de Médecine Interne, HUG, Genève. melanie.bochet@hcuge.ch
Abstract:
Prophylactic antibiotherapy with macrolides is commonly used to prevent bronchiectasis exacerbations. Indeed, there is evidence that macrolides possess immunomodulatory and anti-inflammatory properties, which explains their possible efficacy in this condition despite the presence of resistant germs. This treatment seems to improve the clinical evolution of bronchectasis and to reduce the frequency and intensity of the exacerbations. However, available data concerning this issue is limited and remains insufficient to recommend its systematic use. Until larger studies with long-term follow up are available, the use of macrolides in bronchiectasis should be restricted to selected cases and should take into account their potential side effects.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Microbiota of the Respiratory Tract
Mechanism of Antibiotic Resistance in MRSA
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
